Genomic Health®: Expertise and Experience Brings Genomics to the Practice of Medicine

Genomic HealthSince the company’s founding in 2000, Genomic Health has been revolutionizing personalized treatment for cancer through clinically impactful genomic tests. Genomic Health’s Oncotype DX Breast Recurrence Score, introduced in 2004, and Oncotype DX Colon Recurrence Score, introduced in 2009, have fundamentally changed clinical practice in the management of two major cancers. The Oncotype DX Genomic Prostate Score (introduced in 2013) is having a similar impact, helping to direct treatment to those patients who need it while sparing other patients the side effects of unnecessary therapies.

Genomic Health has a proven track record of performance:

Unsurpassed Global Clinical Evidence and Practice Changing Results

  • Over 30 clinical studies analyzing more than 15,000 tumors1
  • More than 85 peer-reviewed publications and more than 300 posters and abstracts
  • 30% change in treatment in over 30 studies1
  • Global cancer treatment guidelines
  • Reimbursement for breast cancer achieved for over 95% of privately insured U.S. lives, as well as all Medicare beneficiaries

World-class Commercial Laboratory

  • Pathology department comprised of dedicated pathologists with specialized training from leading academic centers in surgical pathology, genitourinary pathology, and/or molecular pathology
  • CLIA-certified, CAP-accredited reference laboratory
  • Precision and reproducibility ensured by rigorous quality control measures
  • Over 350 samples processed daily at centralized lab

Global Reach

  • 20 distribution partners in over 80 countries
  • Over 90 million lives outside of the U.S. covered by reimbursement
  • 13 languages spoken in Customer Service department
  • To date, the Oncotype DX test (for breast, colon and prostate cancer) has been ordered by more than 19,000 doctors in over 90 countries for over 700,000 patients


1. Genomic Health JP Morgan presentation 2/15/15
Next: Breast Recurrence Score Result